Our findings not only elucidate the underlying mechanism by which chemotherapy‐induced drug resistance occurs through increased O‐GlcNAcylation of NRF2 but also provide potential therapeutic targets for lung cancer. This evidence concerns the gene NFE2L2 and lung carcinoma.